Results 61 to 70 of about 427 (127)
Antimicrobial Agents and Chemotherapy, 2020 Manogepix (APX001A) is the active moiety of the novel drug candidate fosmanogepix (APX001). We previously reported the broad-spectrum activity of manogepix but also observed a correlation between increased manogepix and fluconazole MICs.
M. Arendrup, K. M. Jørgensen
semanticscholar +1 more source
Multidrug resistance mechanisms and therapeutic strategies in Candida auris [PDF]
In recent years, Candida auris has emerged as a formidable global health threat due to its multidrug resistance, high transmissibility in healthcare settings, and diagnostic challenges. Unlike most Candida species, C. auris can colonize the skin, persist
Alkaabi, Sara
core +2 more sources
Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review [PDF]
, 2023 The outbreak of a fatal black fungus infection after the resurgence of the cadaverous COVID-19 has exhorted scientists worldwide to develop a nutshell by repurposing or designing new formulations to address the crisis.
A. Sophia +22 more
core +1 more source
Antimicrobial Agents and Chemotherapy, 2020 Manogepix (APX001A) is the active moiety of the drug candidate fosmanogepix (APX001), currently in clinical development for the treatment of invasive fungal infections.
K. M. Jørgensen, K. Astvad, M. Arendrup
semanticscholar +1 more source
Fungal lung disease encompasses a wide spectrum of organisms and associated clinical conditions, presenting a significant global health challenge. The type and severity of disease are determined by underlying host immunity and infecting fungal strain ...
Agarwal, Ritesh +9 more
core +1 more source
Antimicrobial Agents and Chemotherapy, 2018 APX001A is the active moiety of the first-in-class drug candidate APX001. So far, most susceptibility testing studies have examined ≤30 isolates/species, and only one used the EUCAST method.
M. Arendrup +3 more
semanticscholar +1 more source
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. [PDF]
Ibrexafungerp (formerly SCY-078) is the first member of the triterpenoid class that prevents the synthesis of the fungal cell wall polymer β-(1,3)-D-glucan by inhibiting the enzyme glucan synthase.
Alkhazraji, Sondus +8 more
core +1 more source
NOVEL SMALL MOLECULE ANTIFUNGALS FOR INVASIVE FUNGAL INFECTIONS [PDF]
, 2020 Human fungal pathogens cause a range of diseases from benign skin conditions (i.e., ringworm) to thrush, mucosal membrane infections, and life-threatening systemic infections including bloodstream infections (i.e., aspergillosis and candidiasis) and ...
Dennis, Emily
core +1 more source
Bioorganic & Medicinal Chemistry Letters, 2019 Fosmanogepix (APX001) is a first-in-class prodrug molecule that is currently in Phase 2 clinical trials for invasive fungal infections. The active moiety manogepix (APX001A) inhibits the novel fungal protein Gwt1.
Michael Trzoss +6 more
semanticscholar +1 more source
APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
Open Forum Infectious Diseases, 2017 Background Mucormycosis is a life-threatening infection with high mortality that occurs predominantly in immunocompromised patients. APX001A is an antifungal agent that targets Gwt1, an early step in the conserved glycosylphosphotidyl inositol (GPI) post-
Teclegiorgis Gebremariam +7 more
semanticscholar +1 more source